Outsourced Manufacturing: A Swiss Specialty
Unknown to some, Switzerland meanwhile remains both influential and relevant in global pharma circles not just for the obvious core activities of research, discovery and marketing, but also for its…
Since its founding in 1943, the Swiss Tropical Institute (STI), now Swiss Tropical and Public Health Institute (Swiss TPH) has become a world-renowned Institution for teaching, research and services in the field of International Health Development.
The multi- and cross-disciplinary activities and experience of scientific laboratory studies, conceptual clinical work and practical transfer of technical expertise to health system planning and programmes in local, national and partner countries are the building blocks of the Swiss TPH´s success.
Today over 700 colleagues from 40 nations work worldwide for the Swiss TPH in research, teaching and service provision with the single goal to facilitate and contribute to health development worldwide with a strong focus on low and middle income countries.
As an associate institute of the University of Basel, the Swiss TPH takes part in teaching within the medical, philosophy, natural sciences, and historical philosophy faculties, as well as is engaged in post-graduate education and advanced training on national and international levels.
Contact
Swiss Tropical and Public Health Institute
P.O. Box
4002 Basel
Main Secretariat & Travel Clinic:
Socinstrasse 57
4051 Basel
Phone +41 61 284 81 11
Unknown to some, Switzerland meanwhile remains both influential and relevant in global pharma circles not just for the obvious core activities of research, discovery and marketing, but also for its…
With cancer now causing one in eight deaths globally and, in Europe, even outpacing serious cardiovascular conditions in terms of prevalence, Switzerland has long positioned itself firmly at the vanguard…
Indian generics powerhouse Dr. Reddy’s has prioritized biosimilars as a key component of the global organization’s ongoing transition into a specialty pharma company. As one of the first companies…
Worldwide, severe side effects from classic medicine are becoming a health risk in themselves, often misdiagnosed as symptoms of other problems, resulting in further prescriptions, further side effects and unanticipated drug interactions;…
In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at punching well above their weight. After the giants,…
Roche announced strong Group sales growth of seven percent for 2018, partly driven by the launch of MS blockbuster Ocrevus, which CEO Severin Schwan has described as the most successful…
Basel-headquartered pharma giant Novartis announced its financial results for 2018 this week, showcasing full year net sales growth of five percent driven by the strong performance of the company’s pharmaceutical…
The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined…
In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models,…
The past 5 decades have seen monumental strides in healthcare; from the discovery that aspirin prevents blood clotting to the eradication of smallpox. In this exclusive interview, Thomas Cueni, director general…
As the spotlight turns towards optimising supply and delivery chains in pharma logistics, Swiss Post has distinguished itself as one of the early movers in trialling autonomous drone logistics for…
Alexander Bauer, chairman and co-founder of 4PL Central Station, introduces his company’s unique logistics service offering, and the role of fourth party logistics in the future of the pharmaceutical industry.…
See our Cookie Privacy Policy Here
